← Krystal Biotech, Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $0 $0 $2k $8k ($4k) $0 $0 $50.7m $290.5m $389.1m
Cost of goods sold — — $2k $6k — $0 $0 $3.1m $20.1m $23.0m
Research and development $741k $3.2m $7.8m $15.6m $17.9m $27.9m $42.5m $46.4m $53.6m $58.0m
Selling, general and administrative $402k $1.6m $4.2m $6.5m $15.1m $40.4m $77.7m $98.4m $113.7m $146.7m
Operating Expenses $1.1m $4.8m $11.9m $22.1m $33.0m $68.3m $145.2m $160.4m $224.8m $227.8m
Total operating expenses $1.1m $4.8m $11.9m $22.1m $33.0m $68.3m $145.2m $160.4m $224.8m $227.8m
Operating Income (Loss) ($1.1m) ($4.8m) ($11.9m) ($22.1m) ($33.0m) ($68.3m) ($145.2m) ($109.7m) $65.7m $161.3m
Additional Financial Items
Foreign Currency Transaction Gain (Loss), before Tax — — $2k $8k $4k $169k $565k $1.4m $828k ($1.2m)
Gain (Loss) Related to Litigation Settlement — — — — — $560k — — — $0
Realized Investment Gains (Losses) — — — — — — $570k $5.1m $6.1m $6.0m
Product revenue, net $0 $0 $2k $8k ($4k) $0 $0 $50.7m $290.5m $389.1m
Litigation settlement — — — — $0 $0 $25.0m $12.5m $37.5m $0
Income (loss) from operations ($1.1m) ($4.8m) ($11.9m) ($22.1m) ($33.0m) ($68.3m) ($145.2m) ($109.7m) $65.7m $161.3m
Gain from sale of priority review voucher — — — — — $0 $0 $100.0m $0 $0
Interest and other income, net — — $1.0m $3.0m $832k $197k $5.2m $22.6m $29.7m $28.2m
Unrealized gain (loss) on available-for-sale securities, net of tax — — $2k $8k ($4k) ($169k) ($565k) $1.4m ($828k) $642k
Foreign currency translation — — — — — — — ($66k) ($388k) $684k
Comprehensive income — — ($10.9m) ($19.1m) ($32.2m) ($69.7m) ($140.5m) $12.3m $88.3m $206.2m
Basic (in shares) — — — — $18.8m $22.2m $25.5m $27.2m $28.6m $28.9m
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $1.1m $4.8m $11.9m $22.1m $33.0m $68.3m ($140.0m) $12.9m $95.4m $189.5m
Income before income taxes — — — — — ($69.6m) ($140.0m) $12.9m $95.4m $189.5m
Net Income (Loss) Attributable to Parent ($1.1m) ($7.9m) ($10.9m) ($19.1m) ($32.2m) ($69.6m) ($140.0m) $10.9m $89.2m $204.8m
Net Income (Loss) Available to Common Stockholders, Basic ($1.1m) ($7.9m) ($10.9m) ($19.1m) ($32.2m) ($69.6m) ($140.0m) $10.9m $89.2m $204.8m
Earnings Per Share, Basic — — — — ($1.71) ($3.13) ($5.49) $0.40 $3.12 $7.08
Earnings Per Share, Diluted ($1.31) ($1.48) ($0.97) ($1.20) ($1.71) ($3.13) ($5.49) $0.39 $3.00 $6.84
Weighted Average Number of Shares Outstanding, Basic — — — — $18.8m 22.2m 25.5m 27.2m 28.6m 28.9m
Weighted Average Number of Shares Outstanding, Diluted — — — — — 22.2m 25.5m 27.8m 29.7m 30.0m
Research and Development Expense $741k $3.2m $7.8m $15.6m $17.9m $27.9m $42.5m $46.4m $53.6m $58.0m
General and Administrative Expense $402k $1.6m $4.2m $6.5m $15.1m $40.4m $77.7m $98.4m $113.7m $146.7m
Selling, General and Administrative Expense $402k $1.6m $4.2m $6.5m $15.1m $40.4m $77.7m $98.4m $113.7m $146.7m
Current Income Tax Expense (Benefit) $0 $0 $0 $0 $0 $0 $0 $2.0m $6.2m $11.9m
Interest Expense — — — — — $1.5m $0 $0 — —
Operating Lease, Expense — — — — $756k $1.3m — — — —
Income tax benefit (expense) — — — — — $0 $0 ($2.0m) ($6.2m) $15.4m
Income Tax Expense (Benefit) — $0 $0 $0 $0 $0 $0 $2.0m $6.2m ($15.4m)
Interest Income (Expense), Nonoperating, Net — — — — — — — — $29.7m $28.2m

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.